RxDoctor Payments Data

Sunil Mathews, MD

Neurology · Irving, TXNPI 1255437067

Payments from drug & device makers

$20,160in general payments, 2019–2025

Across 1,085 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • EMD Serono, Inc.$1K
  • Pfizer$1K
  • Biogen$1K
  • Lilly USA, LLC$979
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$2081%
  • Food & beverage$19,78998%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)136$2,347
UCB, Inc.71$1,429
EMD Serono, Inc.97$1,325
Pfizer50$1,157
Biogen53$1,039
Lilly USA, LLC57$979
Amneal Pharmaceuticals LLC59$953
Grifols USA, LLC42$924
Genentech USA, Inc.36$837
Sanofi36$694
Teva Pharmaceuticals USA, Inc.28$607
Lundbeck LLC36$586
Catalyst Pharmaceuticals, Inc.31$527
Amgen(2 entities)28$518
Kyowa Kirin, Inc.25$503
Novartis29$499
Sunovion Pharmaceuticals Inc.19$314
Acorda Therapeutics, Inc13$260
AstraZeneca12$256
Biohaven Pharmaceutical Holding Company Ltd.11$231
Eisai Inc.8$226
Argenx US, Inc.10$225
Harmony Biosciences LLC10$214
SK Life Science, Inc.8$213
Upsher-smith Laboratories LLC10$203
MDD US Operations, LLC9$194
Biohaven Pharmaceuticals, Inc.13$184
Adamas Pharmaceuticals, Inc.15$172
Supernus Pharmaceuticals, Inc.10$171
Vanda Pharmaceuticals Inc.6$157
Almatica Pharma LLC6$135
Neurocrine Biosciences, Inc.5$128
CSL Behring6$128
Boston Scientific6$127
Axsome Therapeutics, Inc.6$122
Octapharma USA, Inc.5$113
Scilex Pharmaceuticals Inc.7$107
Jazz Pharmaceuticals Inc.5$106
Acadia Pharmaceuticals Inc5$103
Assertio Therapeutics, Inc.6$94
GE HealthCare5$92
Johnson & Johnson(2 entities)4$74
Takeda Pharmaceuticals U.S.A., Inc.3$69
TG Therapeutics, Inc.3$64
Promius Pharma LLC4$56
Abbott3$55
Bristol Myers Squibb3$50
Mallinckrodt Hospital Products Inc.2$48
Neurelis, Inc.2$48
Merck3$44
Banner Life Sciences, LLC2$40
Impel Pharmaceuticals Inc.2$38
Aucta Pharmaceuticals, Inc.3$38
Avion Pharmaceuticals2$37
Mallinckrodt Enterprises LLC2$32
Arbor Pharmaceuticals, Inc.2$29
Currax Pharmaceuticals LLC2$28
Idorsia Pharmaceuticals US Inc2$28
GRT US Holding, Inc.1$27
Corium, LLC2$25

How this compares

$20,160 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$638,463
Medicare patients
266
Services billed
12,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin13$127,616
Avonex (4 Pack)Interferon Beta-1a13$105,307
RytaryCarbidopa/Levodopa87$75,033
NourianzIstradefylline22$63,037
NeuproRotigotine41$41,028
NamzaricMemantine Hcl/Donepezil Hcl17$25,318
Emgality PenGalcanezumab-Gnlm20$23,316
FycompaPerampanel12$16,632
Emgality SyringeGalcanezumab-Gnlm11$7,581
NayzilamMidazolam11$6,900
Lacosamide30$6,056
Carbidopa-Levodopa ErCarbidopa/Levodopa72$4,327
Entacapone42$3,990
Gabapentin190$3,979
Levetiracetam ErLevetiracetam42$3,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$1,039$105,30713 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$953$75,276101 claims
Kyowa Kirin, Inc.Nourianz$503$63,03722 claims
UCB, Inc.Neupro, Nayzilam$1,429$47,92852 claims
AbbVieNamzaric$2,347$25,31817 claims
Eisai Inc.Fycompa$226$16,63212 claims
Upsher-smith Laboratories LLCTopiramate$203$5513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →